Related by context. All words. (Click for frequent words.) 87 orBec R 60 mifamurtide 59 Zerenex 58 relapsed multiple myeloma 58 systemic immunosuppressive drugs 57 L MTP PE 57 talactoferrin 56 TOCOSOL Paclitaxel 56 ONTAK 56 tamibarotene 56 refractory Hodgkin lymphoma 56 EFAPROXYN 56 tivozanib 56 NEUMUNE 56 TRISENOX ® 56 TELINTRA 56 INC# 55 FOLOTYN 55 Tamibarotene 55 successfully commercialize Iluvien 55 valopicitabine 55 TORISEL 55 Restanza 55 forodesine hydrochloride 55 Valortim 55 LE DT 55 TAFA# 55 velafermin 54 OPAXIO 54 Anturol 54 ISTODAX 54 EOquin 54 YONDELIS 54 albinterferon alfa 2b 54 Anthim 54 ELACYT 54 Amigal 54 Xanafide 54 TRISENOX 54 Gemzar ® 54 registrational trial 54 Allovectin 7 ® 54 OncoVEX GM CSF 54 perifosine 54 ALN RSV# 54 Glufosfamide 54 PXD# 54 Jevtana 54 cintredekin besudotox 54 raxibacumab 54 oral ridaforolimus 54 MyVax R 53 amrubicin 53 OHR/AVR# 53 AGGRASTAT R 53 Clolar ® 53 elotuzumab 53 Bicifadine 53 Allovectin 7 53 GATTEX TM 53 Genasense ® 53 metastatic GIST 53 confirmatory Phase III 53 TELCYTA 53 Marqibo 53 ATryn R 53 TNFerade 53 Fludara 53 IL# PE#QQR 53 EOquin TM 53 pralatrexate 53 oral prodrug 53 Dacogen injection 53 Chemophase 53 Vidaza 53 phase IIb clinical 53 unique alkylating agent 53 MOZOBIL 53 vandetanib 53 #D#C# 53 RECOTHROM 53 Viprinex 53 TRISENOX R 53 satraplatin 53 refractory PTCL 53 forodesine 53 MyVax ® 53 BENLYSTA ® 53 OMAPRO 52 lenalidomide Revlimid R 52 AEG# 52 L BLP# 52 CoFactor 52 Genasense 52 pradefovir 52 Tarceva TM 52 Troxatyl 52 glufosfamide 52 Amrubicin 52 ponatinib 52 pegloticase 52 clofarabine 52 AGGRASTAT ® 52 Gliadel Wafer 52 KIACTA TM 52 Proxinium TM 52 SinuNase 52 Bortezomib 52 Nexavar ® 52 Multikine 52 APF# 52 gastrointestinal GVHD 52 Neulasta ® 52 BrachySil 52 relapsed refractory multiple myeloma 52 omega interferon 52 R sorafenib tablets 52 MAGE A3 ASCI 52 Taxotere ® 52 OvaRex ® MAb 52 LEP ETU 52 EGRIFTA TM 52 bafetinib 52 AzaSite Plus 52 BiovaxID 52 eniluracil 52 torezolid phosphate 52 Azedra TM 52 PEG PAL 52 Cloretazine ® 51 Symadex 51 GTC recombinant human 51 UPLYSO 51 JAK inhibitor 51 PNP inhibitor 51 Phase #b/#a clinical 51 docetaxel Taxotere ® 51 PrevOnco 51 tesetaxel 51 blinatumomab 51 ALN TTR# 51 TREANDA 51 aflibercept 51 Azedra 51 trastuzumab DM1 T DM1 51 Civacir 51 ZEVALIN 51 IRX 2 51 anticancer therapy 51 bevacizumab Avastin ® 51 DAVANAT R 51 Poly ICR 51 Bezielle 51 Exelixis compounds 51 AeroLEF TM 51 Trofex TM 51 INCB# [002] 51 HspE7 51 HuMax CD4 51 Ceflatonin 51 PROVENGE 51 Topical Interferon Alpha 2b 51 Delcath PHP System 51 INTERCEPT platelets 51 Fodosine 51 TLK# 51 Personalized Immunotherapy 51 MDV# 51 severe hypercholesterolemia 51 oral taxane 51 Insegia 51 Neuradiab 51 Aptivus ® 51 custirsen 51 MAXY G# 51 mapatumumab 51 Onalta 51 refractory AML 51 Locteron 51 ThermoDox ® 51 ganetespib 51 ERBITUX 51 Panzem R NCD 51 Generx TM 50 Protexia R 50 Tectin TM 50 confirmatory Phase 3 50 huC# DM4 50 oral deforolimus 50 LEUKINE 50 picoplatin 50 granisetron 50 Hepatocellular Carcinoma HCC 50 ZYBRESTAT 50 pixantrone 50 Genasense ® oblimersen 50 celgosivir 50 refractory CLL 50 KRYSTEXXA TM pegloticase 50 alvespimycin 50 tesmilifene 50 MGCD# [001] 50 lesinurad 50 RhuDex ® 50 CINTREDEKIN BESUDOTOX 50 Intravenous CP 50 humanized anti 50 refractory chronic lymphocytic 50 refractory multiple myeloma 50 ZALBIN 50 Perifosine 50 PANVAC VF 50 PEG Interferon lambda 50 novel VDA molecule 50 INCB# [001] 50 ONCASPAR 50 panitumumab 50 erlotinib Tarceva ® 50 VELCADE 50 IMiDs 50 BrachySil TM 50 Sulonex TM 50 Virulizin R 50 phase IIb III 50 Vandetanib 50 sunitinib malate 50 sorafenib tablets 50 CYT# potent vascular disrupting 50 axitinib 50 interferon gamma 1b 50 BEMA TM Fentanyl 50 Archexin 50 ALIMTA 50 Indaflex TM 50 lapatinib Tykerb 50 ZADAXIN 50 eritoran 50 Solazed TM 50 Romidepsin 50 Bioenvision compounds under 50 ASONEP 50 Ketotransdel 50 Voraxaze ™ 50 R#/MEM # 50 cancer neuroendocrine tumor 50 Cloretazine R VNP#M 50 Myocet 50 cutaneous T cell 50 HuMax EGFr 50 advanced carcinoid 50 Alocrest 50 ENRICH trial 50 Surfaxin LS 50 Leukine ® 50 gefitinib 50 mocetinostat 50 Eligard R 50 Traficet EN 50 ACTEMRA TM 50 tezampanel 50 nonclinical studies 50 autoimmune indications 50 ixabepilone 50 NP2 Enkephalin 49 forodesine HCl 49 romidepsin 49 KNS # 49 recurrent NSCLC 49 EGFR expressing mCRC 49 Stimuvax 49 GRN# 49 GATTEX 49 FOLOTYN ® 49 Onalta ™ 49 BEMA Buprenorphine 49 ApoB SNALP 49 Azixa 49 AP# [003] 49 zanolimumab 49 peginesatide 49 Dacogen 49 sapacitabine 49 oral mTOR inhibitor 49 XmAb# 49 Locteron ® 49 ASA# 49 anticancer agent 49 CIMZIA TM 49 PRT# 49 DAVANAT 49 ALN PCS 49 docetaxel chemotherapy 49 omacetaxine 49 Aflibercept 49 Kamada AAT 49 metaglidasen 49 ISA# [002] 49 Allovectin 7 R 49 Aurexis 49 Mitoxantrone 49 cilengitide 49 Valortim ® 49 PS# [001] 49 ZYBRESTAT fosbretabulin 49 PrevOnco ™ 49 ofatumumab 49 JAK1 49 MEK inhibitors 49 phase IIa clinical 49 Hyphanox 49 plus dexamethasone 49 ThermoDox R 49 CCX# B 49 TRO# 49 Sandostatin LAR Depot 49 tanespimycin 49 otelixizumab 49 SPRYCEL 49 OXi# 49 GED aPC 49 AzaSite Xtra 49 PLX PAD 49 Rasilez Tekturna 49 evaluating tivozanib 49 IoGen 49 CORLUX CORT # 49 Leukine 49 Amplimexon 49 Apaziquone 49 HCV protease inhibitor 49 decitabine 49 IMA# 49 CRMD# 49 MGd 49 UVIDEM 49 PDX pralatrexate 49 Radilex 49 registrational 49 Bioaccelerate compounds under 48 enzastaurin 48 carfilzomib 48 isavuconazole 48 MGCD# MGCD# [001] 48 synthetic retinoid 48 Phase IIIb clinical 48 BCX# 48 AQ4N 48 FavId 48 XL# anticancer compounds 48 2 methoxyestradiol 48 OvaRex R 48 CBLB# 48 DAVANAT ® 48 CR# vcMMAE 48 ARIKACE 48 refractory indolent non 48 obatoclax 48 Folotyn 48 nimotuzumab 48 DCVax R Brain 48 Virulizin ® 48 MAXY alpha 48 eculizumab 48 MEND CABG II 48 vorinostat 48 CA4P 48 docetaxel Taxotere 48 trastuzumab Herceptin R 48 subcutaneous Herceptin 48 radiation sensitizer 48 teduglutide 48 SANCTURA R 48 dose cohort 48 HGS# 48 StemEx 48 veltuzumab 48 Fludara ® 48 NGX# 48 Poly ICLC 48 Genasense R 48 MBP# [001] 48 Canvaxin 48 Homspera 48 BiovaxID TM 48 ThermoDox ® clinical 48 HGS ETR1 48 Metastatic Melanoma 48 refractory acute myeloid 48 mocetinostat MGCD# 48 lymphoma CTCL 48 polymer platinate 48 HGS ETR1 mapatumumab 48 Phase IIb clinical trials 48 liposomal formulation 48 APPRAISE 48 taribavirin 48 PROCHYMAL 48 Daclizumab 48 bardoxolone 48 Aerosurf 48 TYKERB 48 5 Fluorouracil 48 voreloxin 48 mertansine 48 low dose cytarabine 48 EndoTAG TM -1 48 Aeroquin 48 Ixempra 48 RG# [001] 48 tgAAC# 48 StromaCel Inc. 48 DOS# 48 Golimumab 48 Ontak 48 evaluating picoplatin 48 Tyrima 48 Aplidin 48 hematological cancers 48 INCB# [003] 48 G#DT 48 Proellex TM 48 GALNS 48 Omacetaxine 48 Targretin 48 carboplatin paclitaxel 48 Onco TCS 48 MEK inhibitor RDEA# 48 alemtuzumab MS 48 gemcitabine cisplatin 48 Panzem R 48 Zevalin 48 belinostat 48 MAb therapy 48 Ceplene/IL-2 48 zalutumumab 48 chemotherapeutic drug 48 StemEx R 48 limiting toxicity 48 deforolimus 48 KRN# 48 CEQ# 48 docetaxel 48 ThermoDox 47 ANYARA 47 velafermin belinostat 47 oral picoplatin 47 vismodegib 47 vosaroxin 47 StaphVAX R 47 ISIS # 47 Chemokine Therapeutics 47 rALLy clinical trial 47 CBLC# 47 Pralatrexate 47 lintuzumab 47 Viramidine 47 subcutaneous formulation 47 favorable pharmacokinetic profile 47 Targeted Chemotherapy 47 GVAX 47 hormone LHRH antagonist 47 modified glutathione analog 47 drug GAP #B# 47 ILLUMINATE 47 adecatumumab 47 Phase 2a trial 47 brentuximab vedotin 47 CYT# 47 ADVEXIN clinical 47 gemcitabine chemotherapy 47 BiTE antibody 47 investigational monoclonal antibody 47 docetaxel Taxotere R 47 Lymphoseek ® 47 TransVax ™ 47 tezampanel NGX# 47 HCD# [002] 47 ridaforolimus 47 Voreloxin 47 rNAPc2 47 PEG SN# 47 ritonavir boosted danoprevir 47 ABRAXANE 47 CCX# 47 Lenocta TM 47 PLK1 SNALP 47 paclitaxel Taxol ® 47 Annamycin 47 EVIZON TM squalamine lactate 47 neratinib 47 BioNumerik 47 thymalfasin 47 REOLYSIN ® 47 carcinoma HCC 47 pertuzumab 47 Taxotere R 47 CD# antibody [001] 47 XL# XL# XL# XL# 47 Elotuzumab 47 hematologic malignancies 47 Triapine R 47 dacetuzumab 47 Alpharadin 47 cediranib 47 Asentar 47 OncoVEX 47 ADVEXIN 47 HGS ETR2 47 Cintredekin Besudotox 47 Phase Ib study 47 pegylated interferon alpha 2a 47 Sym# 47 Advaxis Phase 47 pemetrexed Alimta 47 Aurora kinase inhibitor 47 Phase Ib 47 anticancer compound 47 ALN VSP 47 Aztreonam lysine 47 talabostat 47 IIa trial 47 elacytarabine 47 Nexavar 47 torsemide ER 47 Solazed ™ 47 Ixabepilone 47 targeted radiotherapeutic 47 orally administered inhibitor 47 HERmark 47 SparVax TM 47 Pivotal Phase III 46 gemcitabine 46 recurrent metastatic ovarian cancer 46 Bioral Amphotericin B 46 PRECISE Trial 46 BNC# 46 SAR# [004] 46 vernakalant oral 46 aflibercept VEGF Trap 46 Nicole Onetto MD 46 Cloretazine R 46 platinum refractory 46 Darinaparsin 46 lumiliximab 46 ara C 46 Vicinium TM 46 NovaBay Aganocide compounds 46 Etubics 46 CCR5 mAb 46 dependent kinase inhibitor 46 Atiprimod 46 Lenocta 46 Xcytrin 46 evaluating satraplatin 46 alfa 2a 46 Taxotere chemotherapy 46 oral proteasome inhibitor 46 PI3K/Akt pathway inhibitor 46 Phase III Pivotal 46 Lexiscan R 46 IMGN# 46 ISTODAX ® 46 cetuximab Erbitux R 46 NB S# 46 Tekmira 46 monoclonal antibody conjugated 46 Exelixis XL# 46 PD2i Cardiac Analyzer 46 Phase #/#a trial 46 capecitabine Xeloda R 46 maximally tolerated dose 46 SUCCEED trial 46 Zevalin R Ibritumomab 46 IAP inhibitors 46 Xeloda ® 46 Urocidin TM 46 Phase 2b study 46 Vidaza ® 46 Stimuvax R 46 Phase 2b clinical 46 BRIM2 46 VEGFR2 inhibitor 46 encapsulates siRNAs 46 RH1 46 CLIRS trial 46 GRNVAC1 46 AVN# [001] 46 BrachySil ™ 46 mitogen activated ERK kinase 46 investigational humanized monoclonal antibody 46 AAG geldanamycin analog 46 DermaVir Patch 46 histone deacetylase inhibitor 46 REOLYSIN R 46 PF # [001] 46 Tovaxin 46 FOLFOX6 chemotherapy regimen 46 XL# XL# 46 ® bortezomib 46 cetuximab Erbitux 46 DCVax ® Brain 46 myeloproliferative disorders 46 Curaxin CBLC# 46 initiate Phase 1b 46 multiple myeloma MM 46 sorafenib Nexavar ® 46 saline placebo 46 PSMA ADC 46 Azixa ™ 46 PROSTVAC ® 46 BLP# Liposome Vaccine 46 MGN# 46 ongoing Phase IIIb 46 phase IIb 46 Belinostat 46 MEK Inhibitor 46 ELEVESS 46 pivotal Phase III 46 XL# [003] 46 #CL# 46 CLORETAZINE TM VNP#M 46 ACAPODENE TM 46 HYVISC R 46 ZACTIMA 46 PRECISE trial 46 S1P antibody 46 ANA# 45 Phase #b/#a 45 Phase Ib clinical trials 45 tiuxetan 45 APOPTONE 45 ZK EPO 45 Revlimid lenalidomide 45 RiVax ™ 45 candidate AQ4N 45 Femprox ® 45 LibiGel Phase III 45 Zemiva ™ 45 Oncaspar 45 Reolysin 45 RAD# [003] 45 Kosan dependence 45 elesclomol 45 liposome formulations 45 ATL# [001] 45 microsphere therapy 45 Intarcia 45 Phase IIb III 45 LPM ™ 45 palifosfamide 45 Thiovir 45 NEUVENGE 45 VEGF Trap 45 antibody MAb 45 Immunotherapeutic 45 Prochymal 45 Epothilones 45 inflammatory autoimmune diseases 45 HER2 positive metastatic breast 45 ALN TTR 45 anticancer therapies 45 REOLYSIN 45 cisplatin gemcitabine 45 Sapacitabine 45 Rhucin ® recombinant 45 Phase IIb clinical 45 OMP #R# 45 intravesical infusion therapy 45 Zemiva TM 45 trastuzumab DM1 45 XP# XP# 45 Onyx Pharmaceuticals Announces 45 demonstrated antitumor activity 45 tremelimumab 45 Phase IIa clinical trials 45 depsipeptide 45 LymphoStat B TM 45 Litx 45 ProLindac 45 oncology indications 45 Panzem 45 AEOL # 45 temozolomide 45 CD# monoclonal antibody 45 GATTEX ® 45 novel topoisomerase 45 angioedema indications 45 GAP #B# 45 AZD# 45 entinostat 45 Exherin 45 NVA# 45 nab paclitaxel 45 TP# CETi 1 45 Synavive 45 class mGluR5 inhibitor 45 Fx #A 45 Oncophage 45 MGCD# MGCD# [002] 45 rheumatoid arthritis thrombocytopenia 45 Combination REOLYSIN R 45 afatinib 45 immunosuppressive compound 45 Hsp# Inhibitor 45 APTIMA HPV assay 45 chemotherapeutic agents 45 CholeraGarde R Peru 45 Phase 2b trial 45 investigational therapies 45 L DOS# 45 Amphinex ® 45 lorvotuzumab mertansine 45 cancer immunotherapies 45 Initiate Phase II 45 T DM1 44 OncoGel 44 Bioral Amphotericin B. 44 tiapamil 44 NEBIDO R 44 Azedra ™ 44 CTA# Injection 44 R bortezomib 44 TACI Ig 44 Daytrana TM 44 SNALP technology 44 huN# DM1 44 telomerase therapeutic 44 TKM PLK1 44 Viral Immunotherapy platform 44 BR.# 44 Protexia ® 44 Perflubutane Polymer Microspheres 44 Ramoplanin 44 prostate cancer AIPC 44 GLP toxicology studies 44 Abiraterone acetate 44 iii Cubist 44 HDAC Inhibitor 44 LE SN# 44 DPX Survivac 44 Tesetaxel 44 Circ Pharma 44 #I TM# 44 BCIRG 44 vaccines oncolytic virus 44 ADVEXIN p# therapy 44 hematological malignancies 44 cytotoxics 44 refractory cutaneous T 44 Phase III clinical 44 plastic photochromic lens 44 AMITIZA lubiprostone 44 Phase Ib II 44 R Bortezomib 44 bortezomib Velcade R 44 LY# [003] 44 Celator 44 olaparib 44 CDK cyclin dependent 44 product platforms AZX# 44 motesanib 44 Innovate Oncology 44 rituximab 44 TNFerade TM 44 Li Fraumeni Syndrome 44 Phase 1b trial 44 multicenter Phase 44 COPREXA 44 metastatic melanoma 44 PRTX 44 mitomycin 44 fallopian tube cancers 44 Tarvacin 44 Cotara 44 Protectan CBLB# 44 JAK2 inhibitor 44 Vitaxin 44 AVE# 44 GVAX Pancreas Vaccine 44 TASKi3 44 Hedgehog Pathway Inhibitor 44 non nucleoside polymerase 44 cytarabine 44 imetelstat 44 metastatic HRPC 44 telaprevir VX 44 Sudhir Agrawal D.Phil 44 Phase Ib clinical 44 bortezomib Velcade ® 44 CAMPATH 44 PEGPH# 44 immunotherapeutic 44 IMC A# 43 personalized immunotherapy 43 Tumour Vascular Disrupting Agent 43 regenerative medicine therapies 43 Zybrestat 43 adjuvant GIST 43 Allovectin 7 r 43 PKC# 43 Talactoferrin 43 ZEVALIN ® 43 GRN#L 43 Auxilium anticipates 43 theseforward looking 43 CORT # 43 Aurora kinase 43 Azedra TM Onalta TM 43 TRAIL receptor antibodies 43 ALN RSV 43 solid tumors 43 Curaxin 43 preclinical studies 43 Phase IIa clinical 43 sodium thiosulfate STS 43 Carfilzomib 43 RITUXAN 43 Provecta 43 oral JAK#/JAK# inhibitor 43 pralatrexate injection folate analogue 43 hypoxia activated prodrug 43 cancer immunotherapy 43 Cardium Therapeutics TM 43 candidates Azedra TM 43 causeactual results 43 Transdel TM 43 RAV# 43 non nucleoside HCV 43 Maximum Tolerated Dose MTD 43 dose cohorts 43 ALN HPN 43 IMC #B 43 fosbretabulin 43 APD# 43 fund BioSante LibiGel 43 CD# CEA 43 antibody MT# 43 AcryMed Incorporated 43 adecatumumab MT# 43 compound AEZS 43 Phase 2a clinical trials 43 antisense drug 43 commercialize ZYFLO CR 43 chemotherapeutic drugs 43 galiximab 43 Airvana anticipates 43 Imprime PGG 43 Phase 2a 43 ONCONASE R 43 CYC# 43 PolyActive ® 43 preclinical toxicology 43 PD2i ® algorithm 43 Cytogen periodic filings 43 MGCD# [002] 43 anti CD# antibodies 43 limiting toxicity DLT 43 EPIX Pharmaceuticals 43 farletuzumab 43 HRPC 43 MyVax R personalized immunotherapy 43 IAP inhibitor 43 stable nucleic acid 43 TLR9 agonists 43 systemic RNAi therapeutic 43 tyrosine kinase inhibitor 43 TASKi2 43 Vivecon 43 PNT# 43 evaluating bafetinib 43 XL# XL# XL# 42 vinorelbine tartrate 42 Guanilib 42 Brentuximab Vedotin SGN 42 selective immunoproteasome inhibitor 42 pivotal Phase 42 eTag assays 42 oral antiviral 42 Neumune 42 ALTROPANE R 42 Telik logo TELINTRA 42 Lovaxin C 42 molecular chaperone regulation 42 ongoing Phase 1b 42 MKC# PP 42 MVA BN 42 Gord Froehlich President 42 Xcellerated T Cells 42 carboplatin 42 hyperthermia therapy 42 commercialize deforolimus 42 Orthopedic Advisory Panel 42 antiangiogenesis therapies 42 LEVP 42 ADSI reliance 42 phenoxodiol 42 RGB # 42 Cytogen dependence 42 hA# 42 COU AA 42 MEK inhibitor 42 anti CD3 monoclonal 42 pancreatic prostate 42 Rexin G 42 EXPAREL ™ 42 Rexahn actual 42 GVAX ® 42 dose escalation Phase 42 risks anduncertainties 42 oral Azacitidine 42 DCVax ® 42 proprietary Capillary Aerosolization Technology 42 OTCBB QTXB 42 Malignant Glioma 42 oncology therapeutics 42 intranasal delivery 42 sapacitabine CYC# 42 oral isoform selective HDAC 42 Virosome Biologicals 42 symbol AVXL 42 Solid Tumors 42 suchstatements 42 Thelin TM 42 lintuzumab SGN 42 Symphony tCGM 42 BRAF inhibitor 42 GVAX R 42 TASE EVGN.TA 42 refractory metastatic 42 radiolabeled TM# 42 PolyMedix compounds 42 ARRY # 42 Phase 1b clinical 42 ORE# 42 metastatic castrate resistant 42 NPC 1C 42 randomized Phase 42 Neuro Hitech 42 evaluating pirfenidone 42 ENMD # 42 Panzem NCD 42 Sepracor anticipates 42 investigational immunotherapy 42 phase Ib 42 GVAX immunotherapy 42 OmniComm intends 42 Nanobody 42 pentadentate logo R 42 hyaluronidase rHuPH# 42 VYVANSE TM lisdexamfetamine 42 Trofex 42 successfully commercialize 42 cleavable linker 42 Selective Electrochemical Tumor Ablation 42 Kevetrin ™ 42 These statementsare 42 Exherin TM 41 TG# [001] 41 AcryMed technologies 41 OTCBB FROI 41 ENMD 41 chemotherapeutics 41 IgG1 monoclonal antibody 41 bavituximab 41 GMX# 41 doublet chemotherapy 41 please visit http:/www.sunesis.com 41 oncolytic viruses 41 Safe Harbors created 41 Budesonide MMX 41 novel anticancer 41 platinum chemotherapeutic 41 uncertaintiesthat 41 Shire Attention Deficit 41 Harry Palmin President 41 Enhance Biotech 41 SNALP 41 RNAi Therapeutic 41 undiscovered accumulations 41 ENABLE Phase 2 41 FOLFIRI chemotherapy 41 historicalfacts 41 MT# MEDI 41 Auxilium assessments 41 cytotoxic agents 41 Asentar TM 41 MAbs 41 delay bone metastases 41 ComfortScan system 41 IMP# 41 lender consents 41 dose escalation trial 41 referenced investigational 41 Tß4 41 website www.nyandcompany.com 41 candidate MyVax 41 Phase Ia 41 risksand uncertainties 41 evaluating Xcytrin